



ETW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: BURTON and DEISHER

Docket No.

3432-B

Serial No.: 10/646,308

Group Art Unit No.:

1646

Filed: August 21, 2003

Examiner:

Jiang, Dong

For: COMPOSITIONS AND METHOD FOR TREATING CARDIOVASCULAR DISEASE

Docket No.: 3432-B

SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

As a means of complying with the duty of disclosure under 37 CFR 1.97 and 1.98, applicants submit a "Supplemental List of References Cited by Applicant" on a modified PTO-1449 form. Since this application was filed after June 30, 2003, copies of U.S. patents and U.S. published patent applications are not required. A copy of all other references are attached for consideration by the Examiner. Kindly acknowledge receipt of this Supplemental Statement and make the cited references of record in the subject application.

Since the submission of the documents listed on the Form PTO-1449 is made before the mailing of the first Office Action in connection with the above-captioned application, no fee under 37 C.F.R. 1.17(p) is believed to be required. However, should it be determined that a fee is necessary, applicants authorize the Commissioner to charge applicants' deposit account no. 09-0089 in an amount necessary to permit consideration of this Supplemental Information Disclosure Statement.

Respectfully submitted,

Diana K. Sheiness

Diana K. Sheiness
Attorney/Agent for Applicants
Registration No.: 35,356
Phone: (206) 265-7818
Date: September 20, 2004

Please send all future correspondence to:

22932

Immunex Corporation
Law Department
1201 Amgen Court West
Seattle, WA 98119-3105
(206) 265-7000

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date appearing below.

9/20/2004
Date

[Signature]
Signature



Modified Form PTO-1449

Atty. Docket No. 3432-B

Serial No. 10/646,308

SUPPLEMENTAL
LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

Applicant BURTON and DEISHER

Filing Date 8/21/2003

Group 1646

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	A1	US2003/0082157A1	05/01/2003	Kwon			
	A2	5,674,704	10/07/1997	Goodwin et al.			
	A3	5,928,893	07/27/1999	Kang et al.			
	A4	6,303,121	10/16/2001	Kwon			
	A5	6,355,779	03/12/2002	Goodwin et al.			
	A6	6,458,934	10/01/2002	Hong et al.			
	A7	6,569,997	05/27/2003	Kwon			
	A8	6,627,200	09/30/2003	Schwarz et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
							YES	NO
	B1	WO 2004/055513	07/01/2004	International				

OTHER DOCUMENTS (Including Publisher, Author, Title, Date, Pertinent Pages, Etc.)

	C1	Melero I et al., "Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors," <i>Nat Med</i> 1997 Jun; 3(6):682-685.
	C2	Miller, RE et al., "4-1BB-Specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner," <i>J Immunol</i> 2002; 169:1792-1800.
	C3	Murillo O et al., "Potentiation of therapeutic immune responses against malignancies with monoclonal antibodies," <i>Clin Cancer Res</i> 2003 Nov; 9:5454-5464.
	C4	Seko Y et al., "Expression of tumour necrosis factor (TNF) ligand superfamily co-stimulatory molecules CD30L, CD27L, OX40L, and 4-1BBL in murine hearts with acute myocarditis caused by Coxsackievirus B3," <i>J Pathol</i> 2001; 195:593-603.
	C5	Seko Y et al., "Expression of tumor necrosis factor ligand superfamily costimulatory molecules CD27L, CD30L, OX40L and 4-1BBL in the heart of patients with acute myocarditis and dilated cardiomyopathy," <i>Cardiovasc Pathol</i> 2002; 11:166-170.
	C6	Tirapu I et al., "Improving efficacy of interleukin-12-transfected dendritic cells injected into murine colon cancer with anti-CD137 monoclonal antibodies and alloantigens," <i>Int J Cancer</i> 2004; 110:51-60.
	C7	Wilcox RA et al., "Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors," <i>J Clin Invest</i> 2002 Mar; 109(5):651-659.

EXAMINER:

Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to applicant.